Monday's TechBio News

Key Takeaways

• Perceptic secured $12M seed to build AI operating system for drug development
• Iterative Health raised $77M Series C to scale AI clinical research network
• Living Models secured $7M and 120 NVIDIA B200 GPUs for foundation models
• Moleculent's $20M round targets functional profiling platform expansion into US market
• Hub71-backed Middle East healthtech firms win awards and raise multi‑million dollars

Pulse Analysis

The biotech sector is witnessing an unprecedented surge of AI‑focused capital, with more than $150 million poured into startups across Europe and the United States this quarter alone. Seed rounds for Perceptic and Living Models illustrate how investors are betting on unified AI operating systems and large‑scale biological foundation models to compress the drug‑development timeline. Meanwhile, Iterative Health’s $77 million Series C underscores the growing demand for AI‑powered clinical‑research networks that can overcome patient‑recruitment bottlenecks and accelerate trial execution across therapeutic areas such as cardiology and obesity.

Strategic collaborations are equally pivotal, as companies combine deep domain data with cutting‑edge machine‑learning expertise. Insilico Medicine’s partnership with Human Life Foundation Models aims to construct the first large‑scale longevity foundation model, leveraging multimodal datasets to uncover novel aging interventions. Similarly, Galux’s joint research pact with AimedBio merges antibody‑drug conjugate technology with AI‑driven protein design, while Ginkgo’s ADME‑One platform integrates high‑throughput ADME screening with AI‑based pharmacokinetic projections, promising earlier go/no‑go decisions and reduced attrition rates. These alliances signal a shift toward platform‑centric models that democratize access to sophisticated AI tools for both large pharma and emerging biotech firms.

Beyond the West, the Middle East’s health‑tech landscape is maturing rapidly, propelled by Hub71’s supportive ecosystem. Startups such as Jade Autism, which captured a $1 million Zayed Sustainability Prize, and Vermillion Health, the rebranded successor of Exsurgo, are leveraging AI to deliver non‑invasive therapeutic solutions. Ovasave’s $1.2 million pre‑seed round and BioSapien’s $5.5 million seed raise for an implantable chemo‑delivery device illustrate the region’s expanding venture pipeline. This confluence of funding, collaboration, and regional incubators is poised to accelerate global biotech innovation, positioning AI as the cornerstone of next‑generation drug discovery and patient care.